In this study, the GLP-1 receptor agonist liraglutide was applied to patients with high BMI, and compared with traditional lifestyle interventions, to study the effect of liraglutide on glucose metabolism and abdominal fat distribution in patients with obesity and T2DM. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.